CJC-1295 and Ipamorelin: The Growth-Hormone Secretagogue Question

"It doesn't give you growth hormone, it just helps your body make more of its own." That line sells more CJC-1295 and ipamorelin than any study does. It is half true, and the half that is missing is the part that matters for your health.

The pairing is one of the most common "protocols" sold by wellness clinics and online research-chemical shops, usually for body composition, sleep, recovery or anti-aging. The science behind the mechanism is real. The science showing that the combination improves any of those outcomes in people is not there. This article walks through both, so that if you discuss them with a clinician, including in our peptide therapy consultations, you know which questions to ask.

The growth hormone axis in two minutes

Growth hormone is released from the pituitary gland in pulses, mostly at night. Two signals from the brain and gut control those pulses:

• GHRH from the hypothalamus says "release".
• Somatostatin says "stop".
• Ghrelin, a hormone made mostly in the stomach, acts on a separate receptor (the growth hormone secretagogue receptor) and amplifies release.

Growth hormone then drives the liver to make IGF-1, which carries many of its effects on tissue growth and metabolism. The system is built with feedback loops: rising IGF-1 tells the brain to ease off.

"Secretagogue" simply means a substance that causes something to be secreted. CJC-1295 works the GHRH side. Ipamorelin works the ghrelin side. The theory behind combining them is that pressing both accelerators at once produces a bigger pulse than either alone.

CJC-1295: what was actually studied

CJC-1295 was developed by the Canadian company ConjuChem in the early 2000s. It is a modified fragment of GHRH attached to a chemical group (the "drug affinity complex", or DAC) that binds to albumin in the blood, letting it last for days instead of minutes.

The key human study is Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism (2006). In healthy adults given single or repeated injections, CJC-1295 produced dose-dependent increases in average growth hormone levels of two- to tenfold lasting six days or more, and IGF-1 stayed elevated for up to 28 days after repeated doses. A companion paper by Ionescu and Frohman (2006, same journal) reported that growth hormone was still released in pulses during this continuous stimulation, rather than in a flat stream.

Notice what those studies measured: hormone levels. They did not show changes in body fat, muscle, strength, sleep, recovery or how anyone felt. Raising a blood marker is a first step in drug development, not an outcome.

Development did not get much further. In July 2006, a phase 2 trial of CJC-1295 in people with HIV-associated abdominal fat was halted after a participant died. At the time, the cause and any relationship to the drug were reported to be under investigation. CJC-1295 was never approved. Meanwhile a different GHRH analogue, tesamorelin, completed its trials for the same condition and was approved in 2010. We explain that drug in tesamorelin: the approved GHRH analogue.

Ipamorelin: selective in animals, disappointing in patients

Ipamorelin is a small five-amino-acid peptide developed by Novo Nordisk in the 1990s. The paper that introduced it, Raun and colleagues in the European Journal of Endocrinology (1998), called it "the first selective growth hormone secretagogue". In animal experiments, it released growth hormone without the large rises in cortisol and prolactin seen with some older secretagogues. That selectivity is where most of today's marketing comes from.

Its human development was aimed not at body composition but at postoperative ileus, the temporary shutdown of gut movement after abdominal surgery, since ghrelin also stimulates the gut. A proof-of-concept randomized trial by Beck and colleagues, published in the International Journal of Colorectal Disease in 2014, tested ipamorelin in patients after bowel resection. According to FDA's review of the evidence, the primary endpoint was not met with statistical significance, secondary measures of gut recovery and hospital stay showed no meaningful differences, and development was discontinued.

There is no published controlled trial showing that ipamorelin improves body composition, sleep quality, recovery or aging in healthy adults.

What regulators have said

Neither peptide is FDA-approved. Both have been part of the long debate over which peptides compounding pharmacies may use.

FDA placed both CJC-1295 and ipamorelin in the category of bulk substances it identified as raising significant safety risks, and both were scheduled for review by its Pharmacy Compounding Advisory Committee in late 2024. In its briefing document on ipamorelin for the October 2024 meeting, FDA recommended against adding it to the list of substances 503A pharmacies may compound from. Its concerns included the potential for immune reactions to peptide impurities and aggregates in injectable products, limited human safety data, reproductive toxicity questions raised by animal studies of ghrelin-receptor drugs, and theoretical effects on reward pathways.

The regulatory picture for peptides has moved repeatedly since then, including the 2026 changes we explain in the July 2026 FDA peptide vote, explained. We are deliberately not stating a current compounding status for CJC-1295 or ipamorelin here, because it has been in flux and a blog post is the wrong place to rely on for it. A licensed clinician should be able to tell you exactly where each one stands on the day you ask. Rules change; verify with FDA.

The "it's your own growth hormone" argument

This is the core sales claim, so it deserves a fair hearing.

What is true: secretagogues work through the pituitary, so release still follows the body's pulsatile pattern, and the feedback loops that restrain growth hormone remain partly in play. That is a genuine pharmacological difference from injecting growth hormone directly.

What is missing:

• More is not automatically better. The point of the peptides is to raise growth hormone and IGF-1 above what your body chooses to make. The consequences of doing that for months or years in healthy adults have not been studied for these compounds.
• IGF-1 has known downsides. The approved GHRH analogue tesamorelin carries label warnings about raised IGF-1, worsened blood sugar, fluid retention and joint pain, and it is contraindicated in active cancer. There is no reason to assume unapproved relatives are exempt from those effects.
• Natural origin is not a safety profile. Your own cortisol, insulin and thyroid hormone are all "natural" and all harmful in excess.

We compare these compounds with growth hormone itself, SARMs and steroids in peptides vs HGH vs SARMs vs steroids.

Athletes and drug testing

The World Anti-Doping Agency Prohibited List bans growth hormone releasing factors under section S2, including GHRH and its analogues such as CJC-1295, and growth hormone secretagogues and growth hormone releasing peptides such as ipamorelin. They are prohibited at all times, in and out of competition. If you are tested under USADA, the NCAA or another sports drug-testing program, check that program’s current list before taking anything; the NCAA and professional leagues keep their own lists, which also ban peptide hormones.

If what you want is better sleep, body composition or recovery

Those are reasonable goals, and a real consultation should start there rather than with a product. That usually means looking at sleep, training load, nutrition, alcohol, medications, and hormone or metabolic problems that labs can identify. Sometimes an approved medication is appropriate. Sometimes the answer is a referral. Sometimes it is a conversation about why an unapproved peptide is not worth the uncertainty.

If you would like a clinician to go through your history and bloodwork with you, you can book a consultation. There is no guarantee that it ends in a prescription, and that is part of what makes the advice worth having.

Common questions

Are CJC-1295 and ipamorelin FDA-approved?

No. Neither has FDA approval for any use. Their availability through compounding pharmacies has changed over time, so ask a clinician for the current position and check FDA sources.

Is CJC-1295 with ipamorelin safe?

Nobody can honestly say, because the combination has not been studied in controlled human trials. The individual human data is limited to short studies measuring hormone levels and one unsuccessful surgical trial.

Is ipamorelin better than sermorelin?

They work through different receptors and neither has head-to-head outcome trials for wellness uses. Sermorelin has a different history: it was once FDA-approved, as we explain in sermorelin: what to know.

Will CJC-1295 or ipamorelin raise my IGF-1?

Raising growth hormone and IGF-1 is the intended effect. The CJC-1295 studies in healthy adults showed sustained IGF-1 increases. Whether that is desirable for a given person is a clinical question, not a given.

Can athletes use CJC-1295 or ipamorelin?

Not in WADA-code sport. Both fall under the S2 category of the Prohibited List at all times.